Vaccine Induced Seroreactivity Following Administration of ALVAC-HIV/AIDSVAX®B/E Identified by Common Anti-HIV Test Kits and Algorithms in Thailand

on behalf of the RV306 Study Group

doi:10.1093/ofid/ofaf578

Vaccine Induced Seroreactivity Following Administration of ALVAC-HIV/AIDSVAX®B/E Identified by Common Anti-HIV Test Kits and Algorithms in Thailand

on behalf of the RV306 Study Group

Research output: Contribution to journal › Article › peer-review

Abstract

Vaccine-induced seroreactivity (VISR) was evaluated in RV306 and was shown to vary markedly (0–32.5%) among 6 HIV diagnostic tests and 84 algorithms. Our data show that selecting the SD Bioline HIV-1/2 assay and algorithms which exclude the ImmunoComb®II Bispot and Alere™ Determine HIV-1/2 assays would almost eliminate VISR in RV306.

Original language	English
Article number	ofaf578
Journal	Open Forum Infectious Diseases
Volume	12
Issue number	10
DOIs	https://doi.org/10.1093/ofid/ofaf578
State	Published - 1 Oct 2025

Keywords

HIV-1
vaccine-induced seroreactivity
VISP
VISR

Access to Document

10.1093/ofid/ofaf578

Cite this

@article{3c30f862cdd74670a862d20730ff23c1,

title = "Vaccine Induced Seroreactivity Following Administration of ALVAC-HIV/AIDSVAX{\textregistered}B/E Identified by Common Anti-HIV Test Kits and Algorithms in Thailand",

abstract = "Vaccine-induced seroreactivity (VISR) was evaluated in RV306 and was shown to vary markedly (0–32.5%) among 6 HIV diagnostic tests and 84 algorithms. Our data show that selecting the SD Bioline HIV-1/2 assay and algorithms which exclude the ImmunoComb{\textregistered}II Bispot and Alere{\texttrademark} Determine HIV-1/2 assays would almost eliminate VISR in RV306.",

keywords = "HIV-1, vaccine-induced seroreactivity, VISP, VISR",

author = "{on behalf of the RV306 Study Group} and Siriwat Akapirat and Elisavet Serti and Punnee Pitisutthithum and Sorachai Nitayaphan and Suwat Chariyalertsak and Chirapa Eamsila and Pornchanok Panjapornsuk and Anocha Kleebmontha and Somsak Chantakulkij and Bhubate Tongchanakarn and Hathairat Savadsuk and Jittima Dhitavat and Sanjay Gurunathan and Faruk Sinangil and Crowell, {Trevor A.} and Michael, {Nelson L.} and Robb, {Merlin L.} and Sandhya Vasan and O{\textquoteright}Connell, {Robert J.}",

year = "2025",

month = oct,

day = "1",

doi = "10.1093/ofid/ofaf578",

language = "English",

volume = "12",

journal = "Open Forum Infectious Diseases",

issn = "2328-8957",

number = "10",

}

TY - JOUR

T1 - Vaccine Induced Seroreactivity Following Administration of ALVAC-HIV/AIDSVAX®B/E Identified by Common Anti-HIV Test Kits and Algorithms in Thailand

AU - on behalf of the RV306 Study Group

AU - Akapirat, Siriwat

AU - Serti, Elisavet

AU - Pitisutthithum, Punnee

AU - Nitayaphan, Sorachai

AU - Chariyalertsak, Suwat

AU - Eamsila, Chirapa

AU - Panjapornsuk, Pornchanok

AU - Kleebmontha, Anocha

AU - Chantakulkij, Somsak

AU - Tongchanakarn, Bhubate

AU - Savadsuk, Hathairat

AU - Dhitavat, Jittima

AU - Gurunathan, Sanjay

AU - Sinangil, Faruk

AU - Crowell, Trevor A.

AU - Michael, Nelson L.

AU - Robb, Merlin L.

AU - Vasan, Sandhya

AU - O’Connell, Robert J.

PY - 2025/10/1

Y1 - 2025/10/1

N2 - Vaccine-induced seroreactivity (VISR) was evaluated in RV306 and was shown to vary markedly (0–32.5%) among 6 HIV diagnostic tests and 84 algorithms. Our data show that selecting the SD Bioline HIV-1/2 assay and algorithms which exclude the ImmunoComb®II Bispot and Alere™ Determine HIV-1/2 assays would almost eliminate VISR in RV306.

AB - Vaccine-induced seroreactivity (VISR) was evaluated in RV306 and was shown to vary markedly (0–32.5%) among 6 HIV diagnostic tests and 84 algorithms. Our data show that selecting the SD Bioline HIV-1/2 assay and algorithms which exclude the ImmunoComb®II Bispot and Alere™ Determine HIV-1/2 assays would almost eliminate VISR in RV306.

KW - HIV-1

KW - vaccine-induced seroreactivity

KW - VISP

KW - VISR

UR - http://www.scopus.com/inward/record.url?scp=105017604742&partnerID=8YFLogxK

U2 - 10.1093/ofid/ofaf578

DO - 10.1093/ofid/ofaf578

M3 - Article

AN - SCOPUS:105017604742

SN - 2328-8957

VL - 12

JO - Open Forum Infectious Diseases

JF - Open Forum Infectious Diseases

IS - 10

M1 - ofaf578

ER -